Latest Amides Stories

Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist(TM) (trametinib) tablets, approved by FDA as single-agent therapies

2013-05-29 20:22:29

- Both approved for unresectable or metastatic melanoma with BRAF V600E mutation; Mekinist also approved for BRAF V600K mutation LONDON and PHILADELPHIA, May 29, 2013 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved both TAFINLAR(®) (dabrafenib) and MEKINIST(TM) (trametinib). Tafinlar is indicated as a single-agent oral treatment for unresectable melanoma (melanoma that cannot be removed by surgery)...

Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports

2013-05-25 23:01:26

The Firm is currently investigating Pradaxa side effect claims on behalf of individuals who allegedly suffered life-threatening internal bleeding while using the blood thinner. New York, New York (PRWEB) May 25, 2013 Pradaxa lawsuits filed on behalf of patients who allegedly suffered serious, life-threatening episodes of internal bleeding while using the blood thinner continue to mount in a federal litigation underway in U.S. District Court, Southern District of Illinois, Bernstein...

DrugRisks Announces New Study Showing Bleeding Risk When Switching to Pradaxa

2013-05-24 23:18:32

http://www.DrugRisks.com is the most useful source on the web for prescription medication alerts, side effects and legal news. Visit us today Kansas City, KS (PRWEB) May 24, 2013 The prescriptin drug resource center DrugRisks.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A recent study suggests patients may not be taking the drug correctly and there is an added risk when switching from drugs like warfarin*. The goal of DrugRisks is to improve...

DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding

2013-05-21 23:23:37

http://www.DrugRisks.com is the most useful source on the web for prescription medication alerts, side effects and legal news. Visit us today. Chicago, IL (PRWEB) May 21, 2013 The prescriptin drug resource center DrugRisks.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A recent study suggests patients taking the drug may be at more risk of death when suffering a head injury than those taking traditional anticoagulants*. DrugRisks was created...

Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports

2013-05-20 23:16:54

Gilman Law LLP is Investigating Byetta Lawsuits on Behalf of Victims of Pancreatic Cancer Side Effects, Allegedly Associated with Byetta, Januvaia, Victoza, and other Diabetes Drugs Known as Incretin Mimetics. Boston, MA (PRWEB) May 20, 2013 Gilman Law LLP, a leading pharmacy law and defective drug plaintiffs’ law firm investigating Byetta lawsuits, is troubled by a new study that reveals that pancreatic cancer reports associated with Byetta and similar type 2 diabetes drugs are...

DrugRisk Update: FDA Investigating Pre-Cancerous Risk of Januvia

2013-05-20 23:04:16

DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Los Angeles, CA (PRWEB) May 20, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for those taking the medications Januvia or Janumet. The FDA is investigating whether these drugs are related to cancer after a study found pre-cancerous cell growth in patients who had died*. DrugRisk was created to...

Court Records Show Increase In Pradaxa Lawsuits, DrugRisk Notes

2013-05-17 23:20:46

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Chicago, IL (PRWEB) May 17, 2013 The prescription drug resource center DrugRisk.com is alerting patients taking the blood thinner Pradaxa of updated news on the site. A federal panel recently advised that the number of claims alleging internal bleeding has nearly tripled in the past few months*. DrugRisk was created to improve...

DrugRisks Update: Latest Court Figures Show Rise In Pradaxa Lawsuits

2013-05-15 23:27:06

http://www.DrugRisks.com is the most useful source on the web for prescription medication alerts, side effects and legal news. Visit us today New York, NY (PRWEB) May 15, 2013 The medication resource center DrugRisks.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A federal panel has disclosed that the amount of patients filing claims alleging internal bleeding from the drug has risen in recent months*. DrugRisks was created to improve the...

Bayer to Present New Data Across Oncology Portfolio at ASCO 2013

2013-05-15 20:23:09

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 - June 4, in Chicago, IL (USA). These data...

Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Advanced Liver Cancer

2013-05-15 04:21:12

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga(®) (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on Nexavar(®) (sorafenib) tablets, an anticancer medicine for the treatment of patients with...